The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials

Drug Safety

Volumn 27, Issue 3, 2004, Pages 203-213

  Meier, Christoph R ^a,b   Wilcock, Karen ^c   Jick, Susan S ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; NEUROLEPTIC AGENT; PROGUANIL; SEDATIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; GENERAL PRACTICE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICAL INFORMATION; MEDICAL RECORD; PANIC; PRIORITY JOURNAL; PSYCHOSIS; RHEUMATOID ARTHRITIS; RISK; RISK FACTOR; STATISTICAL ANALYSIS; SUICIDE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; AGED; ANTIMALARIALS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALARIA; MALE; MIDDLE AGED; PANIC DISORDER; SUICIDE;

EID: 1542315276     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427030-00005     Document Type: Article

References (36)

1. Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313: 525-8
2. Durrheim DN, Gammon S, Waner S, et al. Antimalarial prophylaxis: use and adverse events in visitors to the Kruger National Park. S Afr Med J 1999; 89: 170-5
3. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341 (8856): 1299-303
4. Croft AMJ, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 1996; 347 (8997): 326-8
5. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44 (3): 257-65
6. Corbett EL, Doherty JF, Behrens RH. Adverse events associated with mefloquine [letter]. BMJ 1996; 313: 1552
7. Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52: 269-75
8. Petersen E, Ronne T, Ronn A, et al. Reported side effects to chloroquine, chloroquine plus proguanil and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med 2000; 7: 79-84
9. Van Riemsdijk MM, van der Klauw MM, van Heest JAC, et al. Neuro-psychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52: 1-6
10. Corominas N, Gascon J, Meijas T, et al. Adverse drug reactions associated to the antimalarial chemoprophylaxis. Med Clin (Barc) 1997; 108: 772-5
11. Carme B, Peguet C, Nevez G. Compliance and tolerance of mefloquine and chloroquine + proguanil chemoprophylaxis in French short-term travelers to Africa. Bull Soc Pathol Exot 1997; 90 (4): 273-6
12. Huzly D, Schonfeld C, Beuerle W, et al. Malaria Chemoprophylaxis in German Tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996; 3: 148-55
13. Peregallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93: 73-7
14. Wolters BA, Bosje T, Luinstra-Passchier MJ. No more problems with mefloquine compared to other antimalarial prophylactics. Ned Tijdschr Geneesk 1997; 141 (7): 331-4
15. Angles A, Bagheri H, Montastruc JL, et al. Adverse drug reactions (ADRs) to antimalarial drugs: analysis of spontaneous report from the French pharmacovigilance database (1996-2000). Presse Med 2003; 32: 106-13
16. Lobel HO, Baker MA, Gras FA, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 2001; 8: 167-72
17. Dietz A, Frölich L. Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry 2002; 35: 200-2
18. Fuller SJ, Naraqi S, Gilessi G. Paranoid psychosis related to mefloquine antimalarial prophylaxis. P N G Med J 2002; 45: 219-21
19. Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2500 long-term young travelers to the tropics. J Travel Med 2000; 7: 5-9
20. van Riemsdijk MM, Ditters JM, Sturkenboom MCJM, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002; 58: 441-5
21. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015-21
22. Croft AMJ, Garner P. Mefloquine for preventing malaria in non-immune adult travelers (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2003
23. Murphy JM, Laird NM, Monson RR, et al. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med 2000; 30: 505-14
24. Hagnell O, Lanke J, Rorsman B, et al. Are we entering an age of melancholy? Depressive illnesses in a prospective epidemiological study over 25 years: the Lundby Study, Sweden. Psychol Med 1982; 12: 279-89
25. Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity Surveys of Great Britain: initial findings from the Household Survey. Psychol Med 1997; 27 (4): 775-89
26. Lepine J-P, Gastpar M, Mendlewicz J, et al. Depression in the Community: the First Pan-European Study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19-29
27. Widerlov B, Lindstrom E, von Knorring L. One-year prevalence of long-term functional psychosis in three different areas of Uppsala. Acta Psychiatr Scand 1997; 96 (6): 452-8
28. Ruggeri M, Morven L, Thornicroft G, et al. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry 2000; 177: 149-55
29. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-9
30. Jick H. A database worth saving. Lancet 1997; 350: 1045-6
31. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8
32. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-9
33. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9
34. Dierker LC, Avenevoli S, Stolar M, et al. Smoking and depression: an examination of mechanisms of comorbidity. Am J Psychiatry 2002; 159: 947-53
35. Goodwin R, Hamilton SP. Cigarette smoking and panic: the role of neuroticism. Am J Psychiatry 2002; 159: 1208-13
36. Wittes RC, Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ 1995; 152: 515-7